Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in Singapore. by Wang, Xiao Jun et al.
UC Irvine
UC Irvine Previously Published Works
Title
Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an 
observational study in Singapore.
Permalink
https://escholarship.org/uc/item/79w382rq
Journal
BMC health services research, 14(1)
ISSN
1472-6963
Authors
Wang, Xiao Jun
Wong, Mabel
Hsu, Li Yang
et al.
Publication Date
2014
DOI
10.1186/1472-6963-14-434
License
https://creativecommons.org/licenses/by/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Wang et al. BMC Health Services Research 2014, 14:434
http://www.biomedcentral.com/1472-6963/14/434RESEARCH ARTICLE Open AccessCosts associated with febrile neutropenia in solid
tumor and lymphoma patients – an observational
study in Singapore
Xiao Jun Wang1,2, Mabel Wong3, Li Yang Hsu4 and Alexandre Chan1,2*Abstract
Background: The primary objective was to describe the total direct inpatient costs among solid tumor and
lymphoma patients with chemotherapy-induced febrile neutropenia (FN) and the factors that were associated with
higher direct cost. The secondary objective was to describe the out-of-pocket patient payments and the factors that
were associated with higher out-of-pocket patient payments.
Methods: This was a single-center observational study conducted at the largest cancer center in Singapore. All of
the adult cancer patients hospitalized due to FN from 2009 to 2012 were studied. The primary outcomes were the
total hospital cost and the out-of-pocket patient payments (adjusted by government subsidy) per FN episode.
Univariate analysis and multiple linear regression were conducted to identify the factors associated with higher
FN costs.
Results: Three hundred and sixty seven adult cancer patients were documented with FN-related hospitalizations.
The mean total hospital cost was US$4,193 (95% CI: US$3,779-4,607) and the mean out-of-pocket patient
payment was US$2,230 (95% CI: US$1,976-2,484), per FN episode. The factors associated with a higher total
hospital cost were longer length of stay, severe sepsis, and lymphoma as underlying cancer. The out-of-pocket
patient payment was positively associated with longer length of stay, severe sepsis, lymphoma diagnosed as
underlying cancer, the therapeutic use of granulocyte colony-stimulating factor (GCSF), the private ward class,
and younger patients.
Conclusions: The total hospital cost and out-of-pocket patient payments of FN management in lymphoma
cases were substantial compared with other solid tumors. Factors associated with a higher FN management
cost may be useful for developing appropriate strategies to reduce the cost of FN for cancer patients.
Keywords: Febrile neutropenia, Neutropenia, Fever, Cost analysis, FactorsBackground
Febrile neutropenia (FN) is a common complication in
cancer patients receiving myelosuppressive chemother-
apy. A recent study conducted by our research group [1]
reported that even if cancer patients were given prophy-
lactic myeloid growth factor support, 16.6% of the pa-
tients suffered at least one breakthrough FN episode* Correspondence: phaac@nus.edu.sg
1Department of Pharmacy, Faculty of Science, National University of
Singapore, Block S4A, Level 3, 18 Science Drive 4, Singapore 117543,
Singapore
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unless otherwise stated.during their chemotherapy. FN is also potentially life-
threatening. Inpatient mortality rates of between 4.7%
and 9.5% were recently reported [2-4]. FN often leads to
a chemotherapy dose reduction and to treatment delays,
which may affect the patients’ long-term clinical out-
comes [3,5-7]. A previous study [8] indicated that pa-
tients who received a reduced chemotherapy intensity
(relative dose intensity ≤ 90%) achieved significantly less
survival years than patients who received the optimal
chemotherapy dose intensity.
Aside from its clinical consequences, FN also has a
substantial economic effect, particularly in the inpatient
setting [9]. Three U.S. studies [3,10,11] estimated thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wang et al. BMC Health Services Research 2014, 14:434 Page 2 of 9
http://www.biomedcentral.com/1472-6963/14/434the average costs of FN inpatient management ranged
from US$18,880 to US$22,086. The direct costs for out-
patient management were considerably lower than in-
patient care, at US$985 per episode [11]. Similar trends
with a different cost burden degree were observed in
Europe. A German prospective study [12] analyzed the
influence of FN on the use of health resources and costs
for patients with both solid cancers and lymphoma and
found that the estimated mean direct cost per FN epi-
sode requiring hospital care was €3,950. A Spanish study
[13] found a mean direct cost per episode attributable to
FN of €3,841 in a similar patient population. In a recent
study conducted in Ireland [14], the mean cost per FN
episode in the inpatient setting was estimated to be
€8,915. The cost of FN therefore varies greatly across
different countries and health care systems.
In Singapore, limited data have been reported on the
cost of the management of FN on cancer patients. Cost
studies are therefore needed to make accurate estimates
of the cost of FN on patients with various types of can-
cers. This knowledge can be used to develop further
economic evaluations of the current FN management
strategies, which may help in clinical decision-making.
Therefore, the primary objective of this study was to
describe the total direct inpatient costs among the solid
tumor and lymphoma patients who received inpatient
management of chemotherapy-induced febrile neutro-
penia (FN) and the factors that were associated with
higher direct cost. The secondary objective was to de-
scribe the out-of-pocket patient payments and the fac-
tors that were associated with the higher out-of-pocket
patient payments. We expected this study to provide
an accurate estimate of the cost of FN, reflecting the
local management in Singapore. This study is a funda-
mental requirement for the development of further
economic evaluations of the current FN management
strategies and for reducing the cost of FN on cancer
patients in Singapore
Methods
Study design and setting
This was a secondary analysis of a prospective study [15]
conducted at the National Cancer Centre Singapore
(NCCS) in 2014. In the original study, the clinical effi-
cacy of the adjunctive G-CSF among cancer patients
with febrile neutropenia was evaluated. Clinical data
(demographics, medical history, medication history, and
treatment outcomes) were prospectively obtained from
patients as well as hospital information support system
and the pharmacy prescription database. The complete
methods for the data collection are described in detail
elsewhere [15]. The study was approved by the Sin-
gHealth Institutional Review Board. The NCCS is an
ambulatory cancer center that treats approximately 70%of all of the solid tumor and lymphoma cases in Singapore
[16]. At the NCCS, the majority of the patients who de-
velop FN are hospitalized for treatment until they recover
from their low absolute neutrophil count (ANC) and fever
[17]. The inpatient management of FN follows the guide-
lines from the Infectious Diseases Society of America
(IDSA) [18].
In Singapore, inpatient care is classified into private
ward (Class A and Class B1) and subsidized ward (Class
B2 and Class C) patients. The Class A (single bed) ward is
not subsidized by the government. Different levels of gov-
ernment subsidy are available for the Class B1 (four beds),
Class B2 (six beds), and Class C (open ward) wards for
Singapore citizens and permanent residents [19,20]. The
government subsidizes 0% to 20% of the total hospital bill
for Singapore citizens and permanent residents in the
Class B1 wards. In contrast, citizens and permanent resi-
dents in the Class B2 and Class C wards receive subsidy of
up to 80% of their total bill [20]. The Goods and Services
Tax is absorbed for those who are eligible for subsided
treatment, related services and/or who are staying in the
Class B2 and C wards [19].
Patient population
All of the adult cancer patients (aged 18 years and
above) who received chemotherapy for the treatment of
solid tumors or lymphoma at the NCCS and were hospi-
talized for FN between 2009 and 2012 were included in
this study. The definition of FN was based on the IDSA
guidelines [18]. The cancer type was determined using
the ninth revision of the International Classification of
Diseases – Clinical Modification (ICD-9-CM). Patients
who were hospitalized more than two days before their
FN episode were excluded. If a patient required 10 days
or more of hospitalization after recovering from fever
and low ANC, the patient was also excluded from this
analysis. In patients who had experienced multiple FN-
related hospitalizations during the study period, the first
hospitalization was selected for analysis.
Cost data
The cost data were estimated from billing data obtained
via the financial electronic databases of the NCCS and
the Singapore General Hospital, which included the total
hospital cost, the reimbursement bill, the out-of-pocket
patient payments, and the cost breakdown of out-
of-pocket patient payments (consisted of ward charges,
laboratory charges, radiology charges, prescription charges,
surgical charges, and other charges). A hospital’s perspec-
tive was taken in this study. The FN-related costs included
all of the costs incurred from the day of hospitalization
until the discharge date. These medical costs were
expressed as the total hospital cost and the out-of-pocket
patient payments (adjusted by the government subsidy).
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the underlying cancer were not included. All of the cost
data were adjusted to 2012 Singapore dollars (SG$) using
the health care component of the Singapore Consumer
Price Index [21]. The cost data were then converted to
2012 U.S. dollars (US$) using purchasing power parity
(PPP) conversion rate obtained from the World Bank
(2012; $SG1 = $US0.7157). The out-of-pocket patient pay-
ments was broken down into its individual cost compo-
nents[1]. The information on disaggregated cost of total
hospital cost was not available.
Study outcomes and definitions
The primary outcomes of this analysis were the total
hospital cost and the out-of-pocket patient payments per
FN episode. Univariate and multivariate analyses were
performed to identify the clinical factors which had sig-
nificant associations with a higher total hospital cost or
out-of-pocket patient payments per FN episode. We
evaluated the patient demographics (age, gender, and
ethnicity), major cancer diagnoses (breast cancer, lymph-
oma, gastrointestinal cancer, head and neck cancer, lung
cancer, sarcoma, genitourinary cancer, gynecologic can-
cer, and others), length of stay, treatment with thera-
peutic GCSF, admission source (emergency department,
clinic, and inpatient referral), Multinational Association
of Supportive Care in Cancer (MASCC) score, ward
class (Class A, Class B1, Class B2, and Class C), severity
of sepsis, duration of antibiotics, and the ANC at pres-
entation and nadir. The MASCC score is used to identify
low-risk patients for serious complications of febrile
neutropenia. The patient with higher MASCC score
(score ≥21 points) possesses a lower risk to develop ser-
ious complications from FN [22].
Statistical analysis
The clinical and demographic characteristics were re-
ported for each patient based on a single admission per
patient. We evaluated all of the admissions associated
with FN. Descriptive analyses were used to summarize
the primary study outcomes of this study (total hospital
cost and out-of-pocket patient payments). The means,
median, and 95% confidence intervals (CI) were re-
ported. For the univariate and multivariate analyses, the
total hospital cost and the out-of-pocket patient pay-
ments per FN episode were transformed on the natural
logarithmic scale because an exploratory analysis re-
vealed that the two dependent variables were not nor-
mally distributed. Group comparisons of parametric data
(natural logarithmic transformed cost data) were con-
ducted using Student t-test or analysis of variance
(ANOVA). Scheffe’s Test with Bonferroni correction was
performed if there was a statistically significant finding
through the ANOVA test. This step was performed toidentify the variables of interest which may affect the
outcomes (total hospital cost and out-of-pocket patient
payments) in this study. Pearson’s correlation coefficient
analysis was conducted to identify the variables signifi-
cantly associated with a higher total hospital cost or
out-of-pocket patient payments. After identifying the
variables which were significantly associated with higher
costs, multiple linear regression models were conducted
to estimate the total hospital cost and out-of-pocket pa-
tient payments. IBM SPSS Statistics 21.0 was used for all
of the statistical analysis.
Results
Patient population
Three hundred and sixty seven adult cancer patients
were documented with FN-related hospitalizations be-
tween 2009 and 2012. The average patient age was
54.8 years (range, 18–79), 37.9% of the patients were
male, and 77.1% were of Chinese ethnicity. The most
common primary cancer types were breast cancer
(36.8%), followed by lymphoma (21.5%), gastrointestinal
cancer (10.6%), head and neck cancer (9.3%), and lung
cancer (8.4%) (Table 1). GCSF was used as a therapeutic
treatment (86.9%) in the majority of the FN episodes. In-
patient care commonly occurred (78.7%) in the subsi-
dized wards (Class B2, Class C) (Table 2). The majority
of the patients (90.5%) were Singapore citizens or per-
manent residents.
Total hospital cost
The mean and median total hospital cost per FN episode
for all of the hospitalizations were US$4,193 (95% CI:
US$3,779-4,607) and US$2,837, respectively. A subgroup
analysis by cancer type showed that the patients with
lymphoma had the highest mean total hospital cost of
US$6, 560 (95% CI: US$5,198-7,922), followed by pa-
tients with genitourinary cancer (US$4,898, 95% CI: US
$2,095-7,701), and gynecologic cancer (US$4, 615, 95%
CI: US$3,133-6,097). Breast cancer patients had the low-
est mean total hospital cost (US$2, 898, 95% CI: US
$2,529-3,267) of the identified cancer types (Table 2).
FN episodes that manifested with severe sepsis had a
considerably higher mean cost (US$7,879, 95% CI: US$6,
135-9,623) than those without sepsis (US$3,590, 95% CI:
US$3,240-3,940). Other factors associated with a higher
mean total hospital cost were inpatient referrals (US
$7,238, 95%CI: US$5,637-8,839) and a low MASCC
score (US$5,998, 95% CI: US$4,749-7,247).
Out-of-pocket patient payments
The mean and median out-of-pocket patient payments
per FN episode were US$2,230 (95% CI: US$1,976-2,484)
and US$1,405, respectively. A subgroup analysis by cancer
type revealed that the patients with lymphoma had the
Table 1 Clinical and demographic characteristics of the
subjects
Baseline characteristics Number of patients (n = 367)
Age in years
Mean (SD) 54.8 (12.2)
18-40 (%) 41 (11.2%)
41-60 (%) 202 (55.0%)
61-80 (%) 124 (33.8%)
Gender
Male (%) 139 (37.9%)
Female (%) 228 (62.1%)
Ethnicity
Chinese (%) 283 (77.1%)
Malay (%) 38 (10.4%)
Indian (%) 20 (5.4%)
Other (%) 26 (7.1%)
Cancer Type
Breast CA (%) 135 (36.8%)
Lymphoma (%) 79 (21.5%)
Gastrointestinal CA (%) 39 (10.6%)
Head and Neck CA (%) 34 (9.3%)
Lung CA (%) 31 (8.5%)
Sarcoma (%) 16 (4.4%)
Genitourinary CA (%) 15 (4.1%)
Gynecologic CA (%) 13 (3.5%)
Other/Unknown CA (%) 5 (1.4%)
MASCC Risk
Low (%) 300 (81.7%)
High (%) 67 (18.3%)
Outcome
Death (%) 14 (3.8%)
Recover (%) 353 (96.2%)
SD = standard deviation; CA = cancer; MASCC =Multinational Association of
Supportive Care in Cancer.
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(95% CI: US$2,562-4,216), followed by patients with gyne-
cologic cancer (US$2,877, 95% CI: US$1,560-4,194), and
genitourinary cancer (US$2,629, 95% CI: US$1,131-4,127).
Breast cancer patients had the lowest mean out-of-pocket
patient payments (US$1,567, 95% CI: US$1,318-1,816) of
the known cancer types (Table 2).
The mean out-of-pocket patient payments of FN epi-
sodes with severe sepsis (US$3,358, 95% CI: US$2,586-
4,130) was higher than without sepsis (US$2,044, 95%
CI: US$1,780-2,308). Higher FN out-of-pocket patient
payments were associated with the use of therapeutic
GCSF (US$2,338, 95% CI: US$2,052-2,624) and the pri-
vate wards (Class A (US$5,245, 95% CI: US$3,356-7,134)and Class B1 (US$3,749, 95% CI: US$2,914-4,584)). The
main cost component identified in the out-of-pocket pa-
tient payments was the prescription charges (35.2%),
followed by the ward charges (18.4%) and the laboratory
cost (13.3%). Approximately one quarter of the total
out-of-pocket patient payments was unclassified (29.4%)
(Table 3).
Univariate analysis
The association of cancer types with the total hospital
cost was evaluated. Patients with lymphoma had a sig-
nificantly higher cost (p < 0.001) than patients with other
cancer types. Male patients had a significantly higher
total hospital cost (p < 0.001) than female patients. Other
factors associated with a significantly higher total hos-
pital cost were inpatient referrals (p < 0.001), severe sep-
sis (p < 0.001), and a low MASCC score (p < 0.001)
(Tables 2 and 4). In the correlation analysis, a higher
total hospital cost was also significantly associated with
a longer length of stay (r = 0.86, p < 0.01), a lower ANC
at presentation (r = 0.17, p < 0.01), and a longer time to
recover the ANC (r = 0.16, p < 0.01).
The association of cancer types with the out-of-pocket
patient payments was also evaluated. The lymphoma
group again had a significant higher cost (p < 0.001) than
the other cancer types. The patients in the 18–40 years
age group (p < 0.01) and male patients (p < 0.01) also
had a significantly higher cost than older patients and
female patients, respectively. Other factors associated
with higher out-of-pocket patient payments were treat-
ment with therapeutic GCSF (p < 0.01), inpatient refer-
rals (p < 0.01), severe sepsis (p < 0.001), and a lower
MASCC score (p < 0.05). Patients staying in private
wards (Class A/B1) were associated with a significantly
higher out-of-pocket patient payments (p < 0.001) than
those in the subsided wards (Class B2/C) (Tables 2 and 4).
The correlation analysis revealed that the out-of-pocket
patient payments was positively correlated with a longer
length of stay (r = 0.63, p < 0.01), a lower ANC at presenta-
tion (r = 0.11, p < 0.05), and a longer time to recover the
ANC (r = 0.127, p < 0.05).
Multivariate analysis
Table 5 shows the factors that were found to be signifi-
cantly associated with a higher total hospital cost. The
factors were the length of stay (coefficient = 0.061, 95%
CI: 0.056 ~ 0.065, p < 0.001), lymphoma (coefficient =
0.105, 95% CI: 0.064-0.146, p < 0.001), and severe sepsis
(coefficient = −0.131, 95% CI: 0.086-0.176, p < 0.001).
This multivariate model for the total hospital cost had
an adjusted R2 of 0.782 (p < 0.001) (Table 5).
A separate multivariate model was used to identify the
significant predictors for higher out-of-pocket patient
payments, which are shown in Table 6. The factors were
Table 2 Descriptive analysis of the total hospital cost and the out-of-pocket patient payments (n = 367)
Variables No. (%)
Total hospital cost Out-of-pocket patient payments
per episode, 2012 US$ per episode, 2012 US$
Mean (±95% CI) p value Median Mean (±95% CI) p value Median
All subjects 367 (100%) 4,193 (±414) 2,837 2,230 (±254) 1,405
Age in years
18-40 41 (11.2%) 5,160 (±1,791)
0.182 @
3,456 3,031 (±730)
0.001 @
2,468
41-60 202 (55.0%) 4,089 (±544) 2,723 2,105 (±303) 1,337
61-80 124 (33.8%) 4,044 (±624) 3,022 2,167 (±514) 1,369
Gender
Male 139 (37.9%) 5,286 (±864)
< 0.001 #
3,432 2,795 (±558)
0.006 #
1,510
Female 228 (62.1%) 3,527 (±389) 2,651 1,885 (±218) 1,334
Cancer type
Breast CA 135 (36.8%) 2,898 (±369)
< 0.001 @
2,208 1,567 (±249)
< 0.001 @
1,167
Lymphoma 79 (21.5%) 6,560 (±1,362) 4,159 3,389 (±827) 1,972
Gastrointestinal CA 39 (10.6%) 4,145 (±859) 3,432 1,927 (±541) 1,349
Head and Neck CA 34 (9.3%) 4,565 (±1,665) 3,150 2,502 (±867) 1,486
Lung CA 31 (8.4%) 3,353 (±912) 2,314 1,861 (±947) 1,097
Sarcoma 16 (4.4%) 3,857 (±1,119) 3,479 2,331 (±701) 2,194
Genitourinary CA 15 (4.1%) 4,898 (±2,803) 2,654 2,629 (±1,498) 1,340
Gynecologic CA 13 (3.5%) 4,615 (±1,482) 3,858 2,877 (±1,317) 2,251
Other/Unknown CA 5 (1.4%) 2,707 (±1,199) 2,359 1,403 (±677) 1,364
Therapeutic GCSF
No 48 (13.1%) 3,752 (±1,088)
0.064 #
2,392 1,544 (±384)
0.007 #
1,181
Yes 319 (86.9%) 4,267 (±450) 2,950 2,338 (±286) 1,487
Admission source
ED 195 (53.1%) 3,721 (±503)
< 0.001 @
2,577 1,979 (±259)
0.001 @
1,302
NCCS clinic 121 (33.0%) 3,671 (±594) 2,451 2,069 (±409) 1,377
Inpatient referral 51 (13.9%) 7,238 (±1,601) 4,436 3,570 (±1,163) 2,112
Severe sepsis
No 315 (85.8%) 3,590 (±350)
< 0.001 #
2,571 2,044 (±264)
< 0.001 #
1,283
Yes 52 (14.2%) 7,879 (±1,744) 6,105 3,358 (±772) 2,073
MASCC risk
Low 300 (81.7%) 3,790 (±412)
< 0.001 #
2,571 2,162 (±283)
0.034 #
1,316
High 67 (18.3%) 5,998 (±1,249) 4,436 2,533 (±574) 1,711
Ward class
Class A1 30 (8.2%) 5,879 (±1,875)
0.039 @
4,086 5,245 (±1,889)
< 0.001 @
3,828
Class B1 48 (13.1%) 3,699 (±784) 2,479 3,749 (±835) 2,512
Class B2 194 (52.9%) 3,855 (±540) 2,727 1,696 (±205) 1,256
Class C 95 (25.8%) 4,602 (±923) 3,185 1,600 (±313) 1,100
ED = emergency department; NCCS = National Cancer Centre Singapore; CI = confidence interval; MASCC =Multinational Association of Supportive Care in Cancer;
CA = cancer; @p value from ANOVA test; #p value from two sample t-test, assumed equal variance
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0.060, p < 0.001), lymphoma (coefficient = 0.067, 95% CI:
0.012-0.121, p = 0.017), severe sepsis (coefficient = 0.081,
95% CI: 0.020-0.142, p = 0.009), 18–40 years age group
(coefficient = 0.082, 95% CI: 0.019-0.144, p = 0.011),treatment with therapeutic GCSF (coefficient = 0.101,
95% CI: 0.041-0.161, p = 0.001), and staying on a private
ward (coefficient = 0.408, 95% CI: 0.359-0.457, p < 0.001).
The regression model had an adjusted R2 of 0.691
(Table 6).
Table 3 Cost breakdown of the total out-of-pocket patient payments (n=367)
All of the febrile neutropenia episodes
Median cost (interquartile range), 2012 US$ Mean cost (95% CI), 2012 US$ Percentage breakdown
Ward 230 (145–504) 432 (375–488) 18.4%
Laboratory 171 (120–260) 314 (266–362) 13.3%
Radiology 17 (8–64) 88 (66–110) 3.7%
Prescription 507 (319–891) 829 (720–937) 35.2%
Other/Unknown 383 (226–661) 692 (585–800) 29.4%
Total 1,405 (901–2,442) 2,230 (1,976-2,483) 100%
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In this study, we described the total hospital cost and
out-of-pocket patient payments among solid tumor and
lymphoma patients who received inpatient management
of chemotherapy-induced FN in Singapore. The factors
associated with the total hospital cost and out-of-pocket
patient payments were also identified. The factors that
were found to be associated with a higher total hospital
cost for FN treatment were a longer length of stay,
severe sepsis, and lymphoma. The factors associated
with a higher out-of-pocket patient payments were a
longer length of stay, severe sepsis, lymphoma, the age
group 18–40 years, treatment with therapeutic GCSF
during admission, and staying on a private ward (Class
A or B1).Table 4 Comparisons of costs among subsets of variables ide
Variables Reference (r) Comparator (c)
Out-of-pock
Mean dif
Cancer type Lymphoma
Breast CA 1
Gastrointestinal CA 1
Head & Neck CA 8
Lung CA 1
Sarcoma 1
Genitourinary CA 7
Gynecologic CA 5
Other/Unknown CA 1
Admission source Inpatient referral
NCCS clinic 1
ED admission 1
Age in years 18-40 yrs
41-60 yrs 9
61-80 yrs 8
Ward class
A1
B1 1
B2 3
C 3
B1
A1 −1
B2 2
C 2
ED = emergency department; NCCS = National Cancer Centre Singapore; CA = cance
Scheffe’s Test with Bonferroni correction.When analyzed by cancer type, the mean total hospital
cost was US$6,560 for lymphoma patients, US$2,898 for
breast cancer patients, and ranged from US$3,353 to US
$4,898 for patients with other identified cancers. A simi-
lar pattern was found in previous studies [11,12,23].
Among cancer patients who received inpatient care, the
Bennett [23] study estimated that the mean direct cost
was US$21,601 for lymphoma patients, which was much
more costly than that of breast cancer (US$13,186) or
other cancers (US$12,150). A recently published Spanish
retrospective study [13] reported that the cost was high-
est when lymphoma was the underlying cancer (€4,514),
followed by breast cancer (€3,518) and lung cancer
(€3,310). This difference was probably related to a longer
length of stay due to lymphoma patients suffering FNntified in univariate analysis (n=367)
et patient payments, 2012 US$ Total hospital cost, 2012 US$
ference (r-c) p value@ Mean difference (r-c) p value@
,822 < 0.001* 3,662 < 0.001*
,462 0.411 2,415 0.634
87 0.999 1,995 0.94
,528 0.098 3,207 0.072
,058 1 2,703 0.988
60 0.952 1,662 0.804
12 1 1,945 1
,986 0.969 3,853 0.87
,501 0.002* 3,567 < 0.001*
,591 0.003* 3,517 < 0.001*
26 0.002*
64 0.005*
,496 0.763
,549 < 0.001*
,645 < 0.001*
,496 0.763
,053 < 0.001*
,149 < 0.001*
r; * significant at α = 0.05 after Bonferroni correction; @ Conducted by using
Table 5 Factors associated with the total hospital cost in a regression model (n=367)a
Variablesb Unstandardizedcoefficient (B)
95% CI for B Standard
error
Standardized
coefficient (B) p value
c
Lower bound Upper bound
Length of stay 0.061 0.056 0.065 0.002 0.763 < 0.001
Time to ANC recovery 0.003 −0.003 0.009 0.003 0.024 0.363
ANC at presentation 0.008 −0.054 0.070 0.031 0.007 0.797
MASCC score < 21 −0.013 −0.052 0.026 0.020 −0.017 0.513
Lymphoma 0.105 0.064 0.146 0.021 0.141 < 0.001
Male gender 0.026 −0.006 0.059 0.016 0.042 0.110
Severe sepsis 0.131 0.086 0.176 0.023 0.154 < 0.001
Inpatient referral 0.038 −0.008 0.083 0.023 0.043 0.107
a. Adjusted R2 = 0.782, p < 0.001; b. Only clinically relevant variables that were statistically significant at p value of 0.05 in the univariate analysis were included
in the regression model; c. Bolded p values are statistically significant; ANC = absolute neutrophil count; MASCC =Multinational Association of Supportive Care
in Cancer.
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tients had the longest length of stay (10.1 days) and pa-
tients with female breast cancer had the shortest mean
length of stay (5.9 days) [10]. The length of stay result
was consistent with the cost, as lymphoma had the high-
est mean total hospital cost (US$24,218) and female
breast cancer had the lowest mean cost (US$11,132). As
the length of stay was directly associated with the total
hospital cost, interventions to improve FN management
in future should focus on decreasing the duration of the
hospital stay.
A lower out-of-pocket patient payment was associated
with the Class B2 and C wards. The majority of the pa-
tients were citizens or residents and they received more
subsidies in these wards than in the other ward classes.
The government only subsidizes 0% to 20% of the total
hospital bill for Singapore citizens and permanent resi-
dents in the private Class A and Class B wards [20]. InTable 6 Factors associated with higher out-of-pocket patient
Variablesb Unstandardizedcoefficient (B)
95% C
Lower bound
Length of stay 0.054 0.049
Time to ANC recovery 0.004 −0.004
ANC at presentation −0.003 −0.085
MASCC score < 21 0.019 −0.033
Lymphoma 0.067 0.012
Male gender 0.017 −0.027
Severe sepsis 0.081 0.020
Inpatient referral 0.013 −0.048
18-40 year age group 0.082 0.019
Therapeutic GCSF treatment 0.101 0.041
Private Ward (Class A or B1) 0.408 0.359
a. Adjusted R2 = 0.691, p < 0.001; b. Only clinically relevant variables that were statis
the regression model; c. Bolded p values are statistically significant; ANC= absolute neutr
Association of Supportive Care in Cancer.contrast, citizens and permanent residents in the Class
B2 and Class C wards can receive a subsidy of up to 80%
of their total bill [20]. As the patients’ choice of ward
class may reflect their preference or values as well
as their socioeconomic status, which are an important
determinant in clinical decision-making, future cost-
effective analysis or cost-utility analysis studies should
collect the willingness to pay value separately, based on
the different ward classes.
Prescription charges were the largest component of
the overall out-of-pocket patient payments of FN,
followed by the ward charges, and the laboratory cost.
The medication costs and ward costs were therefore the
main cost drivers in the inpatient management of FN.
A micro-costing method can be used to account for
the cost of the ward and medication, if a more accurate
estimate of the direct medical cost of FN is required.
Prescription charges were identified as the largestpayments in a regression model (n=367)a
I for B Standard
error
Standardized
coefficient (B) p value
c
Upper bound
0.060 0.003 0.614 < 0.001
0.013 0.004 0.031 0.320
0.080 0.042 −0.002 0.948
0.072 0.027 0.022 0.473
0.121 0.028 0.080 0.017
0.060 0.022 0.024 0.452
0.142 0.031 0.085 0.009
0.074 0.031 0.013 0.683
0.144 0.032 0.078 0.011
0.161 0.030 0.100 0.001
0.457 0.025 0.499 < 0.001
tically significant at p value of 0.05 in the univariate analysis were included in
ophil count; GCSF= granulocyte colony-stimulating factor;MASCC=Multinational
Wang et al. BMC Health Services Research 2014, 14:434 Page 8 of 9
http://www.biomedcentral.com/1472-6963/14/434component in the out-of-pocket patient payments because
the reimbursement of healthcare resources in Singapore
differs from other countries. The government subsidy for
cancer patients mainly focuses on the hospitalization
charges and the chemotherapy charges [24]. Certain costly
supportive care medications that are frequently used in
the management of FN, such as G-CSF, are not fully cov-
ered for reimbursement. Therefore, cost-effective analysis
on those medications may be useful to formulate the strat-
egies to reduce patients’ out-of-pocket payments. In
addition, it has been demonstrated that medication errors
(such as inappropriate medication dosing) in the manage-
ment of infectious diseases may contribute to higher
medication costs among patients [25]. Future studies
should aim to lower the cost burden of FN by focusing on
interventions that can improve medication management,
such as having a clinical pharmacist to review prescribed
medications to reduce potential medication errors, and to
optimize the medication management strategies [25].
There are a number of limitations to this study. A
large proportion of the expenses in the total out-of-
pocket patient payments could not be classified. This
may introduce some variability in identifying the main
cost drivers of the cost of FN. We did not capture pa-
tients’ comorbidities in detail, hence we were unable to
analyze the contribution of comorbidities to the cost
burden of FN. Our inclusion criteria were stricter than
other studies, which makes comparisons of the cost esti-
mates difficult [1,3,10,26]. The cost was calculated from
the start date of an FN episode until the discharge date.
Additional costs due to comorbidity or cancer-related
morbidity and mortality were not considered. Those pa-
tients whose discharge date was more than 10 days after
both their fever and ANC recovered were excluded from
the analysis. These criteria were applied so that we only
studied the cost of the management of FN, not the other
costs that are associated with the management of co-
morbidities or cancer due to an extended hospital stay.
Due to the unavailability of data breakdown, micro-
costing on the total hospital cost was not feasible. How-
ever, the average cost-per-case estimates were used to
evaluate the total hospital cost of FN in this study.
Conclusions
In conclusion, the total hospital cost and out-of-pocket
patient payments of FN management in lymphoma cases
were substantially greater than in other solid tumor
cases. A longer length of stay and severe sepsis were as-
sociated with a higher total hospital cost for FN manage-
ment. The factors associated with a higher financial
burden on patients with FN were also identified. These
results may be useful for further economic evaluation to
develop appropriate strategies to reduce the cost of FN
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